Advocacy, Biologics2 days agoFaster Rituximab Infusions in Rheumatology: Evidence Supports Safe, Efficient Care Delivery
Advocacy, Biologics2 weeks agoOptimizing Infusion Center Capacity in 2026: Strategies to Do More Without Expanding Footprint
Advocacy, Biologics1 month agoBiosimilar Adoption in 2026: What Every Specialty Practice Needs to Know
Advocacy2 months agoVertical Integration and the Future of Buy-and-Bill: How Wholesalers Are Rewriting Market Access
Advocacy4 months agoAccumulator and Maximizer Programs: What Specialty Providers Need to Know About the Hidden Costs for Patients
Advocacy4 months agoBeyond the Bag: Building Operational Resilience in Your Buy-and-Bill Infusion Model
Advocacy5 months agoPrivate Labels, Public Consequences: Making Sense of the Stelara Biosimilar Market in 2025
Advocacy5 months agoIs Your Infusion Suite Future-Ready? Infrastructure, Staffing, and Payer Trends to Watch
Advocacy8 months agoEnhancing Neurology Practice Efficiency: How Group Purchasing Can Support Better Care Delivery
Advocacy10 months agoPerformance Metrics in Rheumatology Practices: Strategies for Measuring Success with Remedy GPO
Advocacy, Biologics1 year agoStanding Together Against Policy Changes: Advocacy Resources for Remedy GPO Members
